The burden of hepatitis C virus in the world, China, India, and the United States from 1990 to 2019. 2023

Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.

Hepatitis C virus infection can lead to an enormous health burden worldwide. Investigating the changes in HCV-related burden between different countries could provide inferences for disease management. Hence, we aim to explore the temporal tendency of the disease burden associated with HCV infection in China, India, the United States, and the world. Detailed data on the total burden of disease related to HCV infection were collected from the Global Burden of Disease (GBD) 2019 database. Joinpoint regression models were used to simulate the optimal joinpoints of annual percent changes (APCs). Further analysis of the age composition of each index over time and the relationship between ASRs and the socio-demographic Index (SDI) were explored. Finally, three factors (population growth, population aging, and age-specific changes) were deconstructed for the changes in the number of incidences, deaths, and DALYs. It was estimated that 6.2 million new HCV infections, 0.54 million HCV-related deaths, and 15.3 million DALYs worldwide in 2019, with an increase of 25.4, 59.1, and 43.6%, respectively, from 1990, are mainly due to population growth and aging. China experienced a sharp drop in age-standardized rates in 2019, the United States showed an upward trend, and India exhibited a fluctuating tendency in the burden of disease. The incidence was increasing in all locations recently. HCV remains a global health concern despite tremendous progress being made. The disease burden in China improved significantly, while the burden in the United States was deteriorating, with new infections increasing recently, suggesting more targeted interventions to be established to realize the 2030 elimination goals.

UI MeSH Term Description Entries
D007194 India A country in southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. The capitol is New Delhi. Republic of India
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D016174 Hepacivirus A genus of FLAVIVIRIDAE causing parenterally-transmitted HEPATITIS C which is associated with transfusions and drug abuse. Hepatitis C virus is the type species. Hepatitis C virus,Hepatitis C-Like Viruses,Hepaciviruses,Hepatitis C Like Viruses,Hepatitis C viruses,Hepatitis C-Like Virus
D019057 Quality-Adjusted Life Years A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994) Adjusted Life Year,Healthy Years Equivalent,QALYs,QUALYs,Quality Adjusted Life Year,Quality-Adjusted Life Year,Adjusted Life Years,Healthy Years Equivalents,Quality Adjusted Life Years,Equivalents, Healthy Years,Life Year, Adjusted,Life Year, Quality-Adjusted,Life Years, Adjusted,Life Years, Quality-Adjusted,QUALY,Years, Adjusted Life

Related Publications

Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
January 2024, Frontiers in public health,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
January 2024, Cancers,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
July 2020, China CDC weekly,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
August 2022, Osteoarthritis and cartilage,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
August 2021, Journal of the American Academy of Dermatology,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
December 2023, Archives of osteoporosis,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
January 2022, Frontiers in endocrinology,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
October 2023, Chinese medical journal,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
January 2022, Frontiers in public health,
Jia Yang, and Jin-Lei Qi, and Xiao-Xiao Wang, and Xiao-He Li, and Rui Jin, and Bai-Yi Liu, and Hui-Xin Liu, and Hui-Ying Rao
January 2022, International journal of public health,
Copied contents to your clipboard!